AQR Arbitrage LLC Has $2.47 Million Stake in Abrdn Life Sciences Investors (NYSE:HQL)

AQR Arbitrage LLC decreased its stake in shares of Abrdn Life Sciences Investors (NYSE:HQL - Free Report) by 28.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 188,425 shares of the company's stock after selling 74,853 shares during the period. AQR Arbitrage LLC owned approximately 0.69% of Abrdn Life Sciences Investors worth $2,472,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of HQL. Absolute Investment Advisers LLC acquired a new stake in shares of Abrdn Life Sciences Investors in the fourth quarter worth about $5,242,000. Raymond James Financial Inc. acquired a new position in Abrdn Life Sciences Investors during the 4th quarter worth $3,129,000. LPL Financial LLC grew its position in shares of Abrdn Life Sciences Investors by 82.0% in the fourth quarter. LPL Financial LLC now owns 287,095 shares of the company's stock valued at $3,767,000 after purchasing an additional 129,313 shares during the last quarter. Wolverine Asset Management LLC acquired a new stake in Abrdn Life Sciences Investors in the 4th quarter valued at approximately $1,594,000. Finally, Commonwealth Equity Services LLC increased its position in Abrdn Life Sciences Investors by 3.2% in the 4th quarter. Commonwealth Equity Services LLC now owns 30,119 shares of the company's stock worth $395,000 after buying an additional 933 shares during the period. 32.21% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Abrdn Life Sciences Investors news, major shareholder Saba Capital Management, L.P. sold 48,623 shares of the stock in a transaction on Monday, March 31st. The stock was sold at an average price of $12.58, for a total transaction of $611,677.34. Following the completion of the transaction, the insider now directly owns 3,188,405 shares in the company, valued at $40,110,134.90. This represents a 1.50 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Over the last ninety days, insiders have sold 251,959 shares of company stock worth $3,205,206. Company insiders own 10.06% of the company's stock.

Abrdn Life Sciences Investors Stock Down 1.6 %

Shares of HQL traded down $0.20 during mid-day trading on Wednesday, hitting $12.11. The company's stock had a trading volume of 61,455 shares, compared to its average volume of 127,680. Abrdn Life Sciences Investors has a one year low of $10.55 and a one year high of $15.90. The stock's 50-day moving average is $12.46 and its two-hundred day moving average is $13.49.

Abrdn Life Sciences Investors Cuts Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, March 31st. Shareholders of record on Friday, February 21st were given a $0.47 dividend. The ex-dividend date of this dividend was Friday, February 21st. This represents a $1.88 dividend on an annualized basis and a dividend yield of 15.52%.

About Abrdn Life Sciences Investors

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.